Skip to main content
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1983 Mar 12;286(6368):827–830. doi: 10.1136/bmj.286.6368.827

Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute.

G Ribeiro, M K Palmer
PMCID: PMC1547148  PMID: 6403101

Abstract

A large controlled clinical trial with the admission of 1005 patients was carried out using tamoxifen as adjuvant treatment for women with operable carcinoma of the breast. Results were analysed for the first 906 evaluable patients randomised up to December 1981. After mastectomy premenopausal women were randomised to receive either an irradiation menopause or tamoxifen 20 mg daily for one year. Postmenopausal women were randomised to receive either tamoxifen 20 mg daily for one year or no systemic treatment (controls). Analysis at five years suggested that for premenopausal women there was no significant difference between an irradiation menopause and tamoxifen in terms of survival, local recurrence, or distant metastases. Tamoxifen had no appreciable side effects. For postmenopausal women there was a trend in favour of tamoxifen with regard to survival and incidence of distant metastases, and the difference became statistically significant for those patients with four or more positive axillary nodes. If long term results of these studies show only an improved quality of remaining life with tamoxifen, then this drug could be an important contribution to adjuvant treatment.

Full text

PDF
827

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cole M. P., Jones C. T., Todd I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971 Jun;25(2):270–275. doi: 10.1038/bjc.1971.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Jordan V. C., Dowse L. J. Tamoxifen as an anti-tumour agent: effect on oestrogen binding. J Endocrinol. 1976 Feb;68(02):297–303. doi: 10.1677/joe.0.0680297. [DOI] [PubMed] [Google Scholar]
  3. Lythgoe J. P. Manchester regional breast study. Preliminary results. Lancet. 1978 Apr 8;1(8067):744–747. doi: 10.1016/s0140-6736(78)90859-0. [DOI] [PubMed] [Google Scholar]
  4. Mouridsen H., Palshof T., Patterson J., Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat Rev. 1978 Sep;5(3):131–141. doi: 10.1016/s0305-7372(78)80017-6. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES